Efficacy and safety of fasiglifam (TAK‐875), a G protein‐coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double‐blind, placebo‐controlled, phase III trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 675-681

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus

By Seino Yutaka   Nakajima Hiromu   Miyahara Hajime   Kurita Takashi   Bush Mark A.   Yang Fred   Stewart Murray W.    

Current Medical Research and Opinion, Vol. 25, Iss. 12, 2009-12 ,pp. : 3049-3057

Informa Healthcare

Access to resources Recommend Favorite

A novel CRTH2 antagonist: Single‐ and multiple‐dose tolerability, pharmacokinetics, and pharmacodynamics of ACT‐453859 in healthy subjects

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 7, 2015-07 ,pp. : 787-797

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjects

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 7, 2015-04 ,pp. : 636-648

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

By Kubitza Dagmar   Becka Michael   Roth Angelika   Mueck Wolfgang  

Current Medical Research and Opinion, Vol. 24, Iss. 10, 2008-10 ,pp. : 2757-2765

Informa Healthcare

Access to resources Recommend Favorite